Aradigm there are one or more owners who share jointly in the profits today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily vital sign Bronchiectasis ingestion Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in clients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease show is a chronic, severe vital sign disease and there are currently no approved treatments for this disease in the U.S.

More: - Continued here